3 most recent filings and news items mentioning HAE. Updated every 60 seconds.
Earnings|GuidanceAug 6, 2026Positive
Haemonetics increased Q1 FY27 revenue 5.6% and adjusted earnings per share to $1.14; the company raised total company fiscal 2027 guidance driven by strong business momentum.
View filing at SEC.gov →
LeadershipJul 28, 2026Neutral
Haemonetics has amended and restated its 2019 Long-Term Incentive Compensation Plan to adjust employee, director, and consultant compensation awards. This aligns the economic interests of participants with those of stockholders.
View filing at SEC.gov →
RestructuringJun 5, 2026Neutral
Haemonetics is consolidating its three reportable segments into two: combining Plasma and Blood Center into Apheresis, and renaming Hospital to MedSurg, effective Q1 fiscal 2027. The restructuring aligns external financial reporting with internal business management while maintai
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.